Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intralesional treatment of metastatic melanoma: a review of therapeutic options
Benjamin Weide, Dario Neri, Giuliano Elia
Cancer Immunology Immunotherapy (2017) Vol. 66, Iss. 5, pp. 647-656
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Tumor-related interleukins: old validated targets for new anti-cancer drug development
Sarra Setrerrahmane, Hanmei Xu
Molecular Cancer (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 216
Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy
Noor Momin, Naveen K. Mehta, Nitasha R. Bennett, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 498
Open Access | Times Cited: 177
Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy
Lorenzo Mortara, Enrica Balza, Antonino Bruno, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 124
Engineering IL-2 to Give New Life to T Cell Immunotherapy
Willem W. Overwijk, Mary Tagliaferri, Jonathan Zalevsky
Annual Review of Medicine (2020) Vol. 72, Iss. 1, pp. 281-311
Open Access | Times Cited: 109
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
Cornelia Hutmacher, Dario Neri
Advanced Drug Delivery Reviews (2018) Vol. 141, pp. 67-91
Closed Access | Times Cited: 91
Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation
Patrizia Murer, Dario Neri
New Biotechnology (2019) Vol. 52, pp. 42-53
Open Access | Times Cited: 83
Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies
Sahar Balkhi, Giorgia Bilato, Andrea De Lerma Barbaro, et al.
Vaccines (2025) Vol. 13, Iss. 1, pp. 69-69
Open Access | Times Cited: 1
Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma
Sara Rhaissa Rezende do Reis, Edward Helal‐Neto, Aline Oliveira da Silva de Barros, et al.
Pharmaceutical Research (2021) Vol. 38, Iss. 2, pp. 335-346
Closed Access | Times Cited: 28
Solanum incanum extract (SR-T100) induces melanoma cell apoptosis and inhibits established lung metastasis
Sebastian Yu, Hamm‐Ming Sheu, Chih‐Hung Lee
Oncotarget (2017) Vol. 8, Iss. 61, pp. 103509-103517
Open Access | Times Cited: 35
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives
Mark R. Middleton, Christoph Höeller, Olivier Michielin, et al.
British Journal of Cancer (2020) Vol. 123, Iss. 6, pp. 885-897
Open Access | Times Cited: 30
Intratumorally anchored cytokine therapy
K. Dane Wittrup, Howard L. Kaufman, Michael Schmidt, et al.
Expert Opinion on Drug Delivery (2022) Vol. 19, Iss. 6, pp. 725-732
Open Access | Times Cited: 17
Melanoma neoadjuvant treatment: review and update of recent trials
Marco Ferrari, Bianca Arianna Facchini, Paolo A. Ascierto, et al.
Expert Review of Anticancer Therapy (2025)
Open Access
An intralesional approach with oncolytic viral and immunologic melanoma therapy
Erin Ranaweera
Journal of Dermatology for Physician Assistants (2025) Vol. 19, Iss. 2, pp. 21-28
Closed Access
Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone
David Rafei‐Shamsabadi, Saskia Lehr, Dagmar von Bubnoff, et al.
Cancer Immunology Immunotherapy (2019) Vol. 68, Iss. 9, pp. 1417-1428
Closed Access | Times Cited: 29
DNA binding and evaluation of anticancer activity in vitro and in vivo of iridium(III) polypyridyl complexes
Yuanyuan Zhang, Yi Zhou, Huiwen Zhang, et al.
Journal of Inorganic Biochemistry (2021) Vol. 224, pp. 111580-111580
Closed Access | Times Cited: 21
Analyzing the mechanism by which oyster peptides target IL-2 in melanoma cell apoptosis based on RNA-seq and m6A-seq
Jiaojiao Han, Lingxin Geng, Chenyang Lu, et al.
Food & Function (2023) Vol. 14, Iss. 5, pp. 2362-2373
Closed Access | Times Cited: 9
Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications
Jhalak Dholakia, Alexander C. Cohen, Charles A. Leath, et al.
Current Oncology Reports (2022) Vol. 24, Iss. 4, pp. 389-397
Open Access | Times Cited: 9
Intratumoral Administration of IL2- and TNF-based Fusion Proteins Cures Cancer Without Establishing Protective Immunity
Barbara Ziffels, Francesca Pretto, Dario Neri
Immunotherapy (2018) Vol. 10, Iss. 3, pp. 177-188
Open Access | Times Cited: 16
International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients
J Teras, Hidde M. Kroon, John T. Miura, et al.
Annals of Surgical Oncology (2020) Vol. 27, Iss. 5, pp. 1420-1429
Closed Access | Times Cited: 13
Development of chitosan, pullulan, and alginate based drug-loaded nano-emulsions as a potential malignant melanoma delivery platform
Ghazal Hatami Fard, Zeynab Moinipoor, Salzitsa Anastasova, et al.
Carbohydrate Polymer Technologies and Applications (2022) Vol. 4, pp. 100250-100250
Open Access | Times Cited: 8
Microradiopharmaceutical for Metastatic Melanoma
Thiago Goulart Rosa, Sofia Nascimento dos Santos, Terezinha de Jesus Andreoli Pinto, et al.
Pharmaceutical Research (2017) Vol. 34, Iss. 12, pp. 2922-2930
Closed Access | Times Cited: 10
Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China
Siming Li, Xinan Sheng, Lu Si, et al.
Annals of Surgical Oncology (2017) Vol. 25, Iss. 4, pp. 885-893
Closed Access | Times Cited: 10
How to use neoadjuvant medical treatment to maximize surgery in melanoma
Teresa Amaral, Ioanna Tampouri, Claus Garbe
Expert Review of Anticancer Therapy (2017) Vol. 18, Iss. 2, pp. 121-130
Closed Access | Times Cited: 9
Management of local or regional non‐nodal disease
Jennifer M. Racz, Matthew S. Block, Christian L. Baum, et al.
Journal of Surgical Oncology (2018) Vol. 119, Iss. 2, pp. 187-199
Closed Access | Times Cited: 9
Topical and Intralesional Therapies for in-Transitmelanoma
Michael A. Henderson
Melanoma Management (2019) Vol. 6, Iss. 3
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top